Compare Cytokinetics Inc (CYTK) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Orion Office REIT Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Orion Office REIT Inc trades at $2.17 (market cap $125.50M). The key difference: Cytokinetics Inc is far larger — about 68.7× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Orion Office REIT Inc for 33 Days on average.
| CYTK | ONL | |
|---|---|---|
Market Cap | $8.62B | $125.50M |
Volume | 2,594,626 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $87.26 | $3.00 |
52-Week Low | $54.76 | $1.93 |
Typical Hold Time | 19 Days | 33 Days |
Enterprise Value | $8.72B | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
ONL trades at $2.20, down 3.08% today, with a bearish technical signal. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics appear attractive with P/S of 0.88 and P/B of 0.2, but negative profitability metrics and high debt levels pose concerns. Recent news highlights strategic portfolio repositioning efforts.
Outlook remains challenging with ongoing revenue declines and negative margins, though deep valuation discounts may attract value investors. Key risks include high leverage, office sector exposure, and sustained profitability challenges. Analyst sentiment is mixed with 50% buy and 50% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
